Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma

1 Oct 2019

Abstract excerpt

OBJECTIVE: Ovarian cancer is one of the leading causes of cancer deaths in women. Ovarian cancer is diagnosed at the late stages and generally relapses within 12-14 months of cytoreductive surgery. This is attributed to lack of precise molecular detection methodologies to detect and track the disease. Epigenetic alteration such as aberrant promoter hypermethylation is an important early event that occurs during...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Microtubule and mitosis dynamics
Share to Ovarian cancer diagnosis and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31653147
DOI: 10.31557/apjcp.2019.20.10.3001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian CarcinomaPMID 31653147Read ↗

RASSF1Apromoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNASemantic proximity Read ↗

Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.Semantic proximity Read ↗

Methylation Profile of BRCA1, RASSF1A and ER in Vietnamese Women with Ovarian CancerSemantic proximity Read ↗

The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancerSemantic proximity Read ↗

DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatmentSemantic proximity Read ↗

Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibilitySemantic proximity Read ↗

Aberrant Methylation Status of Tumour Suppressor Genes in Ovarian Cancer Tissue and Paired Plasma SamplesSemantic proximity Read ↗

Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumorsSemantic proximity Read ↗

A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNASemantic proximity Read ↗

Circulating Hypermethylated RASSF1A as a Molecular Biomarker for Diagnosis of Hepatocellular CarcinomaSemantic proximity Read ↗

Methylation and ovarian cancer: Can DNA methylation be of diagnostic use? (Review)Semantic proximity Read ↗

Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.